The use of allogeneic stimulation and exogenous interleukin for syngeneic tumor rejection.
Increased survival in the syngeneic tumor-challenged host was accomplished by the addition of exogenous IL-2 with syngeneic tumor and by simultaneous administration of allogeneic plus syngeneic tumor cells. Whether the mechanisms responsible for this increased longevity are due to the same type of modulation of the immune system is undetermined. These results, however, suggest a therapeutic method of manipulating tumor and IL administration to trigger a sluggish or nonreactive immune system to respond in situations in which it otherwise would not be programmed to react.
D000818:Animals; D006084:Graft Rejection / Q000187:drug effects*; D007111:Immunity, Cellular; D007375:Interleukin-1 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D007377:Interleukin-3 / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D013945:Thymoma / Q000276:immunology*; D013953:Thymus Neoplasms / Q000276:immunology*; D014185:Transplantation, Isogeneic
D007375:Interleukin-1; D007376:Interleukin-2; D007377:Interleukin-3